MILBEMAX 12.5 MG/125 MG TABLETS FOR DOGS

Authorised

- Milbemycin oxime
- Praziquantel

Product identification

Medicine name:
MILBEMAX 12.5 MG/125 MG TABLETS FOR DOGS
Milbemax tabletta kutyáknak A.U.V.

Active substance:
Milbemycin oxime
Praziquantel

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Milbemycin oxime
12.50 milligram(s) / 1.00 Tablet

Praziquantel
125.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AB51

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Hungary

Available in:
Hungary

Package description:
Box of 1 PVC/PE/PVdC/aluminium blister of 2 tablets
Box of 10 PVC/PE/PVdC/aluminium blister of 10 tablets
Box of 5 PVC/PE/PVdC/aluminium blister of 10 tablets
Box of 2 PVC/PE/PVdC/aluminium blister of 10 tablets
Box of 1 PVC/PE/PVdC/aluminium blister of 10 tablets
Box of 1 PVC/PE/PVdC/aluminium blister of 4 tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:
Elanco GmbH

Marketing authorisation date:
23/08/2005

Manufacturing sites for batch release:
Elanco France S.A.S.

Responsible authority:
Directorate Of Veterinary Medicinal Products

Authorisation number:
2329/X/08 MgSzH ÁTI

Date of authorisation status change:
23/08/2005

Reference member state:
France

Procedure number:
FR/V/0135/002

Concerned member states:
Austria Belgium Cyprus Czechia Denmark Finland Germany Greece Hungary Ireland Italy Luxembourg Netherlands Norway Poland Portugal Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet